Role of new PET/CT imaging agents in the diagnosis of hepatocellular carcinoma
Early onset of primary liver cancer is insidious and difficult to diagnose,and most of the patients with liver cancer are already in the middle or late stage of liver cancer when they are diagnosed.These patients are prone to relapse and have a low survival rate after treatment.Recent studies have found that the development of hepatocellular carcinoma is not determined by the unilateral action of epithelial cells or mesenchymal cells,but by the tumor microenvironment formed by the interaction of the two.Tumor microenvironment is mainly composed of tumor-associated fibroblasts,which play an important role in the regulation of tumor cells through the secretion of various cytokines and proteases,etc.Fibroblast-activated protein is one of the products of the tumor microenvironment,and the overexpression of fibroblast-activated protein has been correlated with the growth,invasion,and metastasis of tumors.Radionuclide-labeled fibronectin-activated protein inhibitor(68Ga-FAPI),as a new type of PET/CT imaging agent,has demonstrated good sensitivity and specificity in a variety of malignant tumors,especially in primary hepatocellular carcinoma,due to the lower background uptake in the liver,and has demonstrated higher sensitivity and specificity in the diagnosis of early-stage primary hepatocellular carcinoma,staging of primary hepatocellular carcinoma,and differentiation of benign and malignant liver nodules.This article mainly describes the research progress of 68Ga-FAPI,a new PET/CT imaging agent,in the diagnosis of early primary liver cancer,staging of primary liver cancer,recurrence of primary liver cancer after treatment,and differentiation of benign and malignant liver nodules,with the aim of benefiting the diagnosis and treatment of primary liver cancer in the clinic..
fibroblast-activated protein inhibitorprimary liver cancerPET/CTnuclides
万方数据
维普
